論文 - 詳細
| RRC ID | 71803 |
|---|---|
| 著者 | Asano T, Suzuki H, Kaneko MK, Kato Y. |
| タイトル | Epitope Mapping of Rituximab Using HisMAP Method. |
| ジャーナル | Monoclon Antib Immunodiagn Immunother |
| Abstract |
CD20 is expressed in the B lymphocyte, and an effective target for the detection and treatment of B cell lymphomas. Therefore, CD20 has been studied as a therapeutic target of B cell lymphomas and autoimmune disorders. Specific anti-CD20 monoclonal antibodies (mAbs), such as rituximab, ofatumumab, veltuzumab, and ocaratuzumab, have been developed. Revealing the recognition mechanism of antigen by mAbs could contribute to understanding the function of mAbs and could be useful for the development of vaccine. Rituximab is a mouse-human chimeric anti-CD20 mAb, which was developed and approved for the treatment of the B cell malignancies. Hence, the binding epitope of rituximab for CD20 has been studied. Some reports show that 170-ANPS-173, especially Ala170 and Pro172 of CD20 are important for rituximab binding. However, only phage display results showed that 182-YCYSI-186 of CD20 is also important for rituximab binding to CD20. In this study, we tried to determine the binding epitope of rituximab for CD20 using histidine-tag insertion for epitope mapping (HisMAP) method. The results showed that two regions of CD20 (169-PANPSE-174 and 183-CYSIQ-187) are important for rituximab-binding for CD20. |
| 巻・号 | 41(1) |
| ページ | 8-14 |
| 公開日 | 2022-2-1 |
| DOI | 10.1089/mab.2021.0044 |
| PMID | 35225667 |
| MeSH | Animals Antibodies, Monoclonal* Antigens, CD20* Epitope Mapping Epitopes Mice Rituximab |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | X(Twitter) |
| 各媒体での言及数の合計 | 3 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| 遺伝子材料 | Genome Network Project Human cDNA Clone IRAL012D02 (HGY084874) |